Hisamitsu Pharmaceutical Co Stock Book Value Per Share
| HTSUFDelisted Stock | USD 30.31 0.00 0.00% |
Hisamitsu Pharmaceutical Co fundamentals help investors to digest information that contributes to Hisamitsu Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Hisamitsu Pink Sheet. The fundamental analysis module provides a way to measure Hisamitsu Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hisamitsu Pharmaceutical pink sheet.
Hisamitsu |
Hisamitsu Pharmaceutical Co Company Book Value Per Share Analysis
Hisamitsu Pharmaceutical's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Hisamitsu Pharmaceutical Book Value Per Share | 3,393 X |
Most of Hisamitsu Pharmaceutical's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hisamitsu Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
CompetitionIn accordance with the recently published financial statements, the book value per share of Hisamitsu Pharmaceutical Co is about 3.39 K times. This is 199696.88% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The book value per share for all United States stocks is 75.67% lower than that of the firm.
Hisamitsu Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hisamitsu Pharmaceutical's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Hisamitsu Pharmaceutical could also be used in its relative valuation, which is a method of valuing Hisamitsu Pharmaceutical by comparing valuation metrics of similar companies.Hisamitsu Pharmaceutical is currently under evaluation in book value per share category among its peers.
Hisamitsu Fundamentals
| Return On Equity | 0.0504 | |||
| Return On Asset | 0.0212 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 1.15 B | |||
| Shares Outstanding | 79.53 M | |||
| Shares Owned By Insiders | 26.45 % | |||
| Shares Owned By Institutions | 35.26 % | |||
| Price To Earning | 22.53 X | |||
| Price To Book | 0.97 X | |||
| Price To Sales | 0.02 X | |||
| Revenue | 120.19 B | |||
| Gross Profit | 70.07 B | |||
| EBITDA | 17.3 B | |||
| Net Income | 9.66 B | |||
| Cash And Equivalents | 151.32 B | |||
| Total Debt | 219 M | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 4.46 X | |||
| Book Value Per Share | 3,393 X | |||
| Cash Flow From Operations | 19.2 B | |||
| Earnings Per Share | 1.06 X | |||
| Number Of Employees | 2.78 K | |||
| Beta | 0.51 | |||
| Market Capitalization | 2.45 B | |||
| Total Asset | 302.86 B | |||
| Retained Earnings | 216.56 B | |||
| Working Capital | 133.88 B | |||
| Current Asset | 171.81 B | |||
| Current Liabilities | 37.93 B | |||
| Z Score | 6.6 | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 302.86 B | |||
| Last Dividend Paid | 42.0 |
About Hisamitsu Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hisamitsu Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hisamitsu Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hisamitsu Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in Hisamitsu Pink Sheet
If you are still planning to invest in Hisamitsu Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hisamitsu Pharmaceutical's history and understand the potential risks before investing.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |